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Background
The drug discovery process based on high-throughput
screening (HTS) requires highly demanding efforts to
comply with the strict criteria of homogeneity, sensitivity,
processivity, reproducibility and miniaturization. For
enzymatic targets, the ability to screen in parallel multiple
parameters is a prerequisite to identify the permissive con-
ditions to develop functional assays and to upscale the
protein production to entirely support an HTS campaign,
which generally requires several milligrams of pure pro-
tein.
Results
To fulfill the requirements of the enzymatic assay config-
uration for HTS, we have developed a streamlined process
for the sequential optimization of recombinant expres-
sion, purification and activity of therapeutically-relevant
enzymes, applying automation and miniaturization.
Concerning recombinant expression, we routinely chal-
lenge in parallel three to five chimerical tagged versions of
the target enzyme in 4 different insect cell lines. Insect cell
cultures have been optimized to effectively support
recombinant protein expression in 24-deep-well format,
allowing the simultaneous screening of 36 different con-
ditions for each version of the target.
Tag-based purification by affinity chromatography under-
goes a robot-assisted optimization in 96-well format,
where 8–16 different buffer conditions are screened in
parallel. Selection of the best-supporting purification con-
ditions is determined by integrating data on specific activ-
ity of the enzyme, degree of purity and final production
yield. The identified parameters for expression and purifi-
cation are applied to a large-scale FPLC-based production,
which usually provide the entire amount of enzyme
requested for the assay development.
The enzymatic activity is optimized by screening in 384-
well format pre-assembled plates covering over 250 differ-
ent conditions using HTS-compatible fluorescent or lumi-
nescent readout. In particular, 18 buffers ranging from pH
4.5 to 9.5, 20 monovalent and divalent cations, and 40
additives, including detergents, reducing agents, chela-
tors, organic solvents, stabilizers, and phospholipids, are
challenged in a dose-dependent manner, to determine the
best working conditions for the target enzyme.
Conclusion
The overall optimization on protein expression, purifica-
tion and enzymatic activity for potential drug targets tests
over 800 different conditions, with dramatic impact on
the final assay configuration. We can demonstrate that the
specific activity of the enzyme is increased on average by
200-fold at the end of the process, with cases reaching up
to 600-fold. This result has two direct valuable conse-
quences. First, the assay is configured with maximally
active enzyme preparations, which is considered a hall-
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mark for potentially successful screenings. Second, the
enzyme concentration in the reaction is reduced at its
minimal amount, keeping unaltered the robustness of the
assay. This implies that the sensitivity to potential inhibi-
tors is significantly increased, and screening of large
libraries with difficult-to-express enzymes is made realis-
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